IMVT - NASDAQ

Immunovant, Inc.

IMVT·NASDAQ

$31.15

+1.2%

HealthcareBiotechnology

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.40B

EPS-2.7700

P/E Ratio-11.25

Earnings Date06/04/2026

imvt

Total Liabilities and Equity

Last Annual Value

957.01M

3-Year CAGR

33%

5-Year CAGR

18%

10-Year CAGR

147%

Adjust for Inflation

Immunovant, Inc. Competitors Analysis of Total Liabilities and Equity

IMVT · NASDAQ

Company	Total Liabilities and Equity	CAGR 3Y	CAGR 5Y	CAGR 10Y
Immunovant, Inc. NASDAQ:IMVT	957.01M	33.1%	18.3%	N/A
Soleno Therapeutics, Inc. NASDAQ:SLNO	563.83M	46.1%	73.8%	58.7%
Kymera Therapeutics, Inc. NASDAQ:KYMR	1.74B	44.7%	23.5%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	715.73M	24.8%	27.7%	47.6%
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	1.53B	0.9%	0.1%	11.0%
Dyne Therapeutics, Inc. NASDAQ:DYN	1.19B	93.0%	22.8%	-21.3%
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD	1.56B	27.8%	17.4%	10.8%
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	1.14B	21.4%	26.5%	56.9%
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS	769.28M	30.4%	62.5%	N/A
Akero Therapeutics, Inc. NASDAQ:AKRO	825.89M	12.5%	33.4%	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	937.91M	120.1%	26.2%	N/A

Immunovant, Inc. Fair Value Envelope

IMVT · NASDAQ

Our analysis suggests that IMVT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $31.15, this represents a potential HIDDEN relative to our calculated worth for Immunovant, Inc..

HIDDEN

Intrinsic Value

Current Price: $31.15

Related Guides

Blog Categories

Continue your IMVT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.